New Maintenance Option Approved for Asthma: Breztri
FDA approves Breztri as first single-inhaler triple therapy for asthma in patients 12 and older, offering new maintenance option with reduced exacerbations.

UNIPHARMA INSIGHTS
FDA approves Breztri as first single-inhaler triple therapy for asthma in patients 12 and older, offering new maintenance option with reduced exacerbations.
Chiesi's $1.9B acquisition of KalVista signals a strategic expansion in rare immunology, with implications for rare disease treatment supply and commercialization.
Chiesi acquires KalVista for $1.9B, adding oral HAE drug Ekterly. The deal boosts rare disease portfolio with a differentiated on-demand treatment.
A new integrated polygenic risk score tool for eight cardiovascular conditions enables early risk identification and may shift preventive cardiology workflows.
Chiesi acquires KalVista for $1.9bn, securing first oral HAE therapy Ekterly. The deal transforms HAE attack treatment, shifting from injectables to oral, with implications for supply chain, hospital formularies, and market access in UK and EU.
Precision immunotherapy for SLE targets specific immune pathways, shifting from broad immunosuppression to mechanism-based therapies. Implications for drug development and market access.
Reference pages
A
Drug shortage supplier is tracked by UniPharma when it has a clear effect on sourcing, regulation, access, or commercial execution for pharma teams.
Early Access Medicine is tracked by UniPharma when it has a clear effect on sourcing, regulation, access, or commercial execution for pharma teams.
rld sourcing is tracked by UniPharma when it has a clear effect on sourcing, regulation, access, or commercial execution for pharma teams.
Unlicensed Medicines is tracked by UniPharma when it has a clear effect on sourcing, regulation, access, or commercial execution for pharma teams.